An interventional study of Impact and Glucose load in Stomach Neoplasms and Esophageal Neoplasms, sponsored by Dan Azagury. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-05.
Sponsored by Dan Azagury · Not applicable, Interventional, and Treatment
The aim of this study is to demonstrate the influence of peri-operative nutrition on the post-operative complications, preservation of lean body mass and length of stay after gastrectomy or oesophagectomy.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 43 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →This is the only study on the registry with Dan Azagury as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
Dietary Supplement: Impact · Dietary Supplement: Glucose load
No immunonutrition, no glucose load, no early enteral immunonutrition
Preoperative 5 day oral Impact and early post-operative enteral Impact
Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
Also known as: PreOp Nutricia
Rate of post-operative complications
Time frame: 30 days
Length of stay
Time frame: 30 days
Quality of life
Time frame: 1 year
Body composition
Time frame: 1 year
This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.